The clinical spectrum of fever, also known as pyrexia, presents a significant diagnostic and therapeutic challenge. It demands a comprehensive approach for effective management in clinical practice. This article aims to provide a succinct overview of the principles of fever management.
Pyrexia is a complex physiological response to disease, often a sign of underlying infection, inflammation, or malignancy. It is critical to understand the underlying pathophysiology to devise an appropriate treatment plan. A thorough history, physical examination, and judicious use of investigations are key to identifying the etiology of fever.
The diagnostic evaluation of pyrexia involves a step-wise approach. Initial assessment involves detailed history taking and physical examination, followed by basic investigations like complete blood count, urine analysis, and chest X-ray. If initial investigations are inconclusive, more advanced diagnostics, such as CT scans, MRI, or specific serological tests, may be warranted.
Treatment of pyrexia primarily involves addressing the underlying cause. Symptomatic relief can be achieved with antipyretics. However, the use of antipyretics should not overshadow the importance of treating the primary disease. Early and appropriate antibiotic therapy is crucial in cases of infectious etiology. In cases of non-infectious causes, specific therapies targeting the underlying condition are required.
Follow-up is an integral part of fever management. It ensures resolution of the fever and monitors for potential complications. Regular follow-ups allow for timely adjustments to the treatment plan, if necessary.
Managing pyrexia requires a systematic approach, combining a thorough diagnostic evaluation with targeted treatment strategies. It's crucial to remember that while symptomatic relief is important, the primary focus should be on treating the underlying cause. Regular follow-ups are essential to ensure effective management and to monitor for potential complications.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation